Takeda Oncology
Judd Caulfield is a seasoned legal professional with extensive experience in the pharmaceutical and biotechnology sectors. Currently serving as Senior Counsel at Takeda Oncology since July 2018, Judd advises on various regulatory and promotional matters. Previous roles include serving as an Attorney at Axiom and Cubist Pharmaceuticals, where responsibilities included drafting key business agreements and supporting clinical trial negotiations. As Vice President of Legal Affairs and Data Privacy at ConnectEDU, Judd oversaw a wide range of legal issues including M&A and corporate governance. With a strong foundation in corporate law from Ropes & Gray LLP and experience in marketing and business development, Judd holds a JD magna cum laude from Suffolk University Law School, an MA from Emerson College, and a BA from Bowdoin College.
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.